

Guidance document
Transfer of marketing authorisation

Identification number: ZL404_00_001

Version: 1.3

Valid from: 01.05.2023

List of contents

| | | |
|----------|---|----------|
| 1 | Terms, definitions, abbreviations | 3 |
| 1.1 | Abbreviations..... | 3 |
| 2 | Introduction | 3 |
| 2.1 | Legal framework..... | 3 |
| 3 | Objective | 3 |
| 4 | Scope | 3 |
| 5 | Description | 3 |
| 5.1 | Description of the process | 3 |
| 5.1.1 | Application and documentation..... | 3 |
| 5.1.2 | Consequences of the transfer..... | 4 |
| 5.1.3 | Exceptions, transitional arrangement..... | 4 |
| 5.1.3.1 | Sale of batches already released..... | 4 |
| 5.1.3.2 | Changes to packaging, to Information for healthcare professionals and to Patient information..... | 4 |
| 5.1.4 | Change to the name of the medicinal product..... | 5 |
| 5.1.5 | Modification of the logo or corporate design | 5 |
| 5.1.6 | Packaging elements and product information leaflets | 5 |
| 5.1.7 | Publication of the medicinal product information..... | 5 |
| 5.2 | Fees | 5 |
| 5.3 | Review | 5 |

1 Terms, definitions, abbreviations

1.1 Abbreviations

| | |
|-----------------|---|
| FeeO-Swissmedic | Ordinance on the Fees charged by the Swiss Agency for Therapeutic Products of 14 September 2018 (SR 812.214.5) |
| TPA | Federal Act of 15 December 2000 on Medicinal Products and Medical Devices (Therapeutic Products Act, SR 812.21) |
| TPO | Ordinance of 21 September 2018 on Therapeutic Products (Therapeutic Products Ordinance) (SR 812.212.21) |

2 Introduction

This guidance document describes the requirements and preconditions (including the documentation to be submitted) for an application to transfer authorisations for human and veterinary medicinal products. Since this guidance document is aimed at administrative bodies, it does not directly specify the rights and obligations of private individuals.

2.1 Legal framework

Art. 10 TPO and Art. 11 and Annex 1 FeeO-Swissmedic.

3 Objective

Swissmedic uses this document first and foremost as a resource for applying the legal provisions on authorisation in a uniform and equitable manner. The publication of the guidance document is designed to make it clear to third parties what requirements must be fulfilled according to the practice of Swissmedic.

4 Scope

The guidance document is applicable in the Infrastructure, Authorisation and Market Surveillance divisions to applications to transfer authorisations for medicinal products to a new marketing authorisation holder.

5 Description

5.1 Description of the process

The transfer of the authorisation comprises the transfer of all rights and obligations associated with the marketing of a medicinal product. The authorisation status of a medicinal product is not affected by the transfer to a new marketing authorisation holder.

5.1.1 Application and documentation

The future marketing authorisation holder must submit to Swissmedic **at least three months** before the planned transfer date a written application requiring approval to transfer the authorisations from

the previous (current) marketing authorisation holder to a new one (the applicant). (see application type 5328 OT *Übertragung ZL*).

The application must contain:

- a) A declaration of assignment bearing the legally valid signatures (as shown in the entry in the Commercial Register) of the previous marketing authorisation holder, stating the name of the medicinal products to be transferred;
- b) The form *Transferring an authorisation HMV4* completed in full by the future marketing authorisation holder (the applicant).

Swissmedic may request further documentation as necessary.

5.1.2 Consequences of the transfer

With the transfer of authorisation, all obligations associated with the authorisation of a medicinal product are transferred in their entirety to the new authorisation holder. In particular, this means that the latter alone is authorised to release new batches for the market.

If batches that were manufactured under the responsibility of the former authorisation holder have to be released for the market, the new authorisation holder is responsible for this. The latter must ensure that it has all the information it needs to confirm that the batch was produced in accordance with Good Manufacturing Practice (GMP), that a valid manufacturer's batch certificate has been issued in accordance with Art. 5a TPA and that the batch meets the formal requirements for authorisation.

5.1.3 Exceptions, transitional arrangement

5.1.3.1 Sale of batches already released

Unless there are particular grounds for doing so, batches already placed on the market will not be recalled. This means that batches which are already on the market (at wholesale and retail level) may remain on the market unchanged until the end of their shelf life and be sold in the regular way. If the former authorisation holder has a permit for wholesale trading in medicinal products, it may continue – in its capacity as wholesaler – to sell those batches which it released for sale prior to the transfer of authorisation. If the new authorisation holder also has a permit for wholesale trading medicinal products, it is possible that an agreement may be concluded between the former and the new authorisation holder for the assumption of batches already released for the market. Unless aspects relating to GDP are affected, however, such an agreement will come under private law.

5.1.3.2 Changes to packaging, to Information for healthcare professionals and to Patient information

To avoid any interruption of distribution or the destruction of batches already manufactured, the new authorisation holder is entitled during the transitional period of up to one year to indicate the new authorisation holder on newly released batches by way of stickers affixed to the outer packaging and without making any other alterations to the packaging of the medicinal product or to other elements. After one year at the latest, the authorisation holder may only release and place on the market batches featuring the new authorisation holder. This is subject to the provisions and requirements of the TPO and the TPLRO.

5.1.4 Change to the name of the medicinal product

A change to the name of the medicinal product is not possible in connection with the application for transfer of the authorisation. For this, a separate application must be submitted to the Authorisation division of Swissmedic.

5.1.5 Modification of the logo or corporate design

Simultaneous modification of the logo or corporate design as part of an application to transfer the authorisation will be the responsibility of the authorisation holder. This means that it is not necessary to submit any documentation to Swissmedic for this purpose, provided the logo or corporate design has already been approved by Swissmedic at an earlier date.

If no logo or corporate design has been approved for the future authorisation holder, this will be evaluated as part of the transfer. A pack showing the logo or corporate design must be enclosed with the transfer application.

Swissmedic will only review the logo or corporate design (but not the other text on the pack) and no authorised text will be returned to the authorisation holder.

An additional fee based on the work involved will be charged for this evaluation.

5.1.6 Packaging elements and product information leaflets

The new marketing authorisation holder may only market the transferred medicinal product with packaging elements and package leaflets displaying the name of the new marketing authorisation holder. No modifications must be made to either the text or packaging design apart from the exceptions listed in sections 5.1.3 and 5.1.5.

5.1.7 Publication of the medicinal product information

The new authorisation holder is responsible for the correct publication of the information for healthcare professionals and patient information texts as of the time when the authorisation is transferred.

5.2 Fees

The fees stated in FeeO-Swissmedic apply.

5.3 Review

Swissmedic may verify the correct implementation of the measures in accordance with Art. 58 para. 2 TPA and instigate measures as appropriate in accordance with Art. 66 TPA. Art. 86 para. 1 letter a TPA also applies.

Change history

| Version | Change | sig |
|---------|--|----------|
| 1.3 | New layout, no content adjustments to the previous version. | dei |
| 1.2 | Modification of the logo or corporate design | gf, mb |
| 1.1 | Formal adjustments to the header and footer No content adjustments to the previous version. | dei |
| 1.0 | New rules regarding sale of batches already released and implementation of HMV4 | fua, stb |